D3-GHR Polymorphism and Turner Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00443144
Recruitment Status : Completed
First Posted : March 5, 2007
Last Update Posted : December 3, 2015
Information provided by (Responsible Party):
Gerhard Binder, University Hospital Tuebingen

Brief Summary:

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome.

Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

Condition or disease Intervention/treatment
Turner Syndrome Short Stature Drug: recombinant human growth hormone

Study Type : Observational
Official Title: D3-Growth Hormone Receptor Polymorphism and Total Effect of Recombinant Human Growth Hormone on Growth in Girls With Turner Syndrome
Study Start Date : May 2005
Actual Primary Completion Date : April 2007
Actual Study Completion Date : May 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   38 Months to 14 Years   (Child)
Sexes Eligible for Study:   Female

Inclusion Criteria:

  • Turner syndrome defined by a structural aberration or lack of the X chromosome.
  • Growth velocity less than 2 cm/year at the time of final analysis (= final height).

Exclusion Criteria:

  • Age <3.5 or >14 years at start of GH therapy,
  • GH peak serum levels < 8 ng/ml in two independent tests,
  • Thelarche at start or during the first year of treatment,
  • Oxandrolone therapy for any time and a duration of GH therapy less than 2 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00443144

University-Children's Hospital
Tübingen, Germany, 72076
Sponsors and Collaborators
University Hospital Tuebingen
Principal Investigator: Gerhard Binder, M.D. PhD University-Children's Hospital Tübingen

Responsible Party: Gerhard Binder, Pediatric Endocrinology, University Hospital Tuebingen Identifier: NCT00443144     History of Changes
Other Study ID Numbers: TS-TUE-FH1
First Posted: March 5, 2007    Key Record Dates
Last Update Posted: December 3, 2015
Last Verified: December 2015

Keywords provided by Gerhard Binder, University Hospital Tuebingen:
growth hormone receptor polymorphism
growth promoting therapy

Additional relevant MeSH terms:
Turner Syndrome
Gonadal Dysgenesis
Primary Ovarian Insufficiency
Pathologic Processes
Disorders of Sex Development
Urogenital Abnormalities
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Sex Chromosome Disorders
Chromosome Disorders
Genetic Diseases, Inborn
Gonadal Disorders
Endocrine System Diseases
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs